MIGUEL ANGEL
SANZ ALONSO
CATEDRÁTICO/A DE UNIVERSIDAD
Hospital Universitari Germans Trias i Pujol
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitari Germans Trias i Pujol (43)
2024
-
Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience
Annals of Hematology, Vol. 103, Núm. 2, pp. 451-461
-
Total body irradiation versus thiotepa/busulfan-based conditioning regimens for myeloablative allogeneic stem cell transplantation in adults with acute lymphoblastic leukemia
Bone Marrow Transplantation, Vol. 59, Núm. 8, pp. 1137-1145
2023
-
Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia
Blood Advances, Vol. 7, Núm. 1, pp. 167-173
-
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia
British Journal of Haematology
2022
2021
-
A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia
Cancer, Vol. 127, Núm. 12, pp. 2003-2014
-
Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study
Transplantation and Cellular Therapy, Vol. 27, Núm. 4, pp. 311.e1-311.e10
-
Measurable residual disease in elderly acute myeloid leukemia: Results from the PETHEMA-FLUGAZA phase 3 clinical trial
Blood Advances, Vol. 5, Núm. 3, pp. 760-770
2020
-
Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols
European Journal of Haematology, Vol. 104, Núm. 3, pp. 162-169
2019
-
An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens
Leukemia and Lymphoma, Vol. 60, Núm. 4, pp. 1030-1035
-
Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy
Leukemia and Lymphoma, Vol. 60, Núm. 5, pp. 1146-1155
-
Real life outcomes of patients aged ≥75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry
Leukemia and Lymphoma, Vol. 60, Núm. 11, pp. 2720-2732
2018
-
Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions
Experimental Hematology, Vol. 62, pp. 24-32
-
Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy
Leukemia, Vol. 32, Núm. 1, pp. 21-29
2017
-
Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia
New England Journal of Medicine, Vol. 376, Núm. 9, pp. 836-847
-
Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation
Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380
-
Single umbilical cord blood with or without CD341 cells from a third-party donor in adults with leukemia
Blood Advances, Vol. 1, Núm. 15, pp. 1047-1055
2015
-
All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: A matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies
Annals of Hematology, Vol. 94, Núm. 8, pp. 1347-1356
-
Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: Phase Ib/II panobidara study
Haematologica, Vol. 100, Núm. 10, pp. 1294-1300
2014
-
Incidence, risk factors, and outcome of bacteremia following autologous hematopoietic stem cell transplantation in 720 adult patients
Annals of Hematology, Vol. 93, Núm. 2, pp. 299-307